Loading...

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry

Eliglustat is a first‐line oral therapy for adults with Gaucher disease type 1 (GD1) with extensive, intermediate, or poor CYP2D6‐metabolizer phenotypes (90% of patients). We report real‐world outcomes after 2 years of eliglustat therapy in the International Collaborative Gaucher Group Gaucher Regis...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Am J Hematol
Main Authors: Mistry, Pramod K., Balwani, Manisha, Charrow, Joel, Kishnani, Priya, Niederau, Claus, Underhill, Lisa H., McClain, Monica R.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Inc. 2020
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497238/
https://ncbi.nlm.nih.gov/pubmed/32438452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25875
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!